GlassScriptPhysician profile
Mercy Viator
NPI 1467914077
$14,042.76
in general payments reported to CMS, 2019-2025
34 companies · $3,848 in 2025
The $3,848 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $528 · 2022: $1,470 · 2023: $3,986 · 2024: $4,211 · 2025: $3,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $1,813 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,132.51 |
| Consulting Fee | $1,812.50 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,063.94 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $2,042.12 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $1,155.84 | 2023-2024 | Vtama |
| Leo Pharma INC. | $1,131.65 | 2022-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $1,035.64 | 2021-2025 | |
| Abbvie INC. | $926.52 | 2023-2025 | |
| Incyte Corporation | $685.96 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $642.49 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Regeneron Healthcare Solutions, INC. | $629.98 | 2022-2025 | Dupixent, Libtayo |
| Pfizer INC. | $515.70 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $453.03 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $435.81 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $399.45 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $360.55 | 2023-2025 | Tremfya |
| Organon LLC | $320.62 | 2025 | Vtama, Hadlima |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $315.30 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $252.69 | 2023-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $166.43 | 2021-2025 | Cabtreo, Arazlo, Siliq |
| Almirall LLC | $84.45 | 2021-2024 | Klisyri |
| Vyne Pharmaceuticals INC. | $70.94 | 2021 | |
| Kyowa Kirin, INC. | $47.77 | 2023-2025 | Poteligeo |
| Strata Skin Sciences, INC. | $39.58 | 2025 | Xtrac |
| Sebela Pharmaceuticals INC. | $37.42 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $29.00 | 2025 | Acthar |
| Journey Medical Corporation | $27.42 | 2022 | |
| Verrica Pharmaceuticals INC. | $26.44 | 2023 | Ycanth |
| Blueprint Medicines Corporation | $25.34 | 2023 | |
| Glaxosmithkline, LLC. | $24.58 | 2023 | Shingrix, Arexvy |
| Helsinn Therapeutics (U.S.), INC. | $17.25 | 2023 | Valchlor |
| Botanix Sb INC | $17.12 | 2025 | Sofdra |
| Nabriva Therapeutics, Plc | $17.00 | 2022 | |
| Genentech USA, INC. | $16.67 | 2021 | |
| Krystal Biotech INC | $14.85 | 2025 | Vyjuvek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.21 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mercy Viator listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.